Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.

Affiliation

Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China. Electronic address: [Email]

Abstract

The use of adjuvant chemotherapy (ACT) in completely resected stage IB non-small cell lung cancer (NSCLC) is still controversial. The divergent outcomes of prospective trials have created uncertainty as to the utility of ACT in stage IB NSCLC. This study assesses the effect of postoperative adjuvant chemotherapy in stage IB patients in clinical practice.

Keywords

Adjuvant chemotherapy,Cancer-specific survival,Disease free survival,Non-small cell lung cancer,Propensity-score matching,

OUR Recent Articles